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Quality of response to immunosuppressive therapy and long-termoutcomes for pediatric severe aplastic anemia remain incompletelycharacterized. Contemporary evidence to inform treatment of
relapsed or refractory severe aplastic anemia for pediatric patients is also
limited.    The clinical features and outcomes for 314 children treated from
2002 to 2014 with immunosuppressive therapy for acquired severe aplastic
anemia were analyzed retrospectively from 25 institutions in the North
American Pediatric Aplastic Anemia Consortium. The majority of subjects
(n=264) received horse anti-thymocyte globulin (hATG) plus cyclosporine
(CyA) with a median 61 months follow up. Following hATG/CyA, 71.2%
(95%CI: 65.3,76.6) achieved an objective response.  In contrast to adult
studies, the quality of response achieved in pediatric patients was high,
with 59.8% (95%CI: 53.7,65.8) complete response and 68.2% (95%CI:
62.2,73.8) achieving at least a very good partial response with a platelet
count ≥50x109L.  At  five years post-hATG/CyA, overall survival was 93%
(95%CI: 89,96), but event-free survival without subsequent treatment was
only 64% (95%CI: 57,69) without a plateau.  Twelve of 171 evaluable
patients (7%) acquired clonal abnormalities after diagnosis after a median
25.2 months (range: 4.3-71 months) post treatment. Myelodysplastic syn-
drome or leukemia developed in 6 of 314 (1.9%).  For relapsed/refractory
disease, treatment with a hematopoietic stem cell transplant had a superior
event-free survival compared to second immunosuppressive therapy treat-
ment in a multivariate analysis (HR=0.19, 95%CI: 0.08,0.47; P=0.0003).
This study highlights the need for improved therapies to achieve sustained
high-quality remission for children with severe aplastic anemia.
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ABSTRACT
Introduction
Acquired severe aplastic anemia (SAA) is a rare disorder
characterized by peripheral bi- or pancytopenia and bone
marrow (BM) hypoplasia.  Initial therapy for younger
patients with SAA is a matched sibling hematopoietic
stem cell transplantation (HSCT) or immunosuppressive
therapy (IST) if a matched sibling donor is not available.1
There is a paucity of data for children with SAA treated
during the modern era from the ethnically and geographi-
cally diverse population of North America.  Pediatric stud-
ies from the National Institutes of Health,2 the Japanese
Childhood Aplastic Anemia Study Group,3-6 Brazil,7 and
the Severe Aplastic Anemia Working Party of the
European Group for Blood and Marrow Transplant
(SAAWP-EBMT)8,9 have been reported.  However, diagnos-
tic evaluation for constitutional disorders has been limit-
ed, and duration of follow up has often been variable and
short. Many published studies report outcomes with rab-
bit anti-thymocyte globulin (rATG) due to the withdrawal
of horse ATG (hATG) from some European and Asian
markets in 2007; however, a large prospective study of
upfront rATG versus hATG reported inferior response rates
and lower survival with rATG.10 Thus, contemporary data
to inform therapeutic decisions in pediatric patients treat-
ed with IST in North America are of interest given inter-
national differences in treatment regimens, recent
advances in diagnosis of genetic marrow failure disorders,
improvements in HSCT outcomes, and better supportive
care. 
To facilitate collaborative clinical studies of pediatric
aplastic anemia, a consortium of 25 institutions (now
numbering 39) across North America, named the North
American Pediatric Aplastic Anemia Consortium
(NAPAAC), was formed in 2014.11 The urgent need for
evidence-based guidelines for patient management in
pediatric SAA was highlighted by a NAPAAC survey of
clinical practices of member institutions which revealed
considerable variability in diagnostic evaluation and man-
agement.11 Recognizing the challenges of performing a
prospective trial to address these critical knowledge gaps,
NAPAAC conducted a retrospective study of presentation
and outcomes of pediatric patients diagnosed from 2002
to 2014 with SAA and treated with IST with a minimum
of two years of follow up in member institutions. The
objectives of the study were to determine the rates of
response and survival following IST, to assess rates of
clonal abnormalities, and to explore patient-specific fac-
tors contributing to survival, refractory disease, relapse,
and clonal progression following IST. This NAPAAC effort
represents the first large study of pediatric SAA reflecting
the racially diverse population of children afflicted by SAA
across multiple centers in North America. These contem-
porary data from a large number of pediatric patients will
inform future studies of additional diagnostic or prognos-
tic testing, and guide evidence-based clinical management.
Methods
Patients
A retrospective chart review was conducted by member institu-
tions of all patients aged 1-20 years treated with IST as the first
therapy for pediatric SAA between 1st January  2002 and 30th June
2014 for whom follow up was available for a minimum of 24
months or until death. This study was approved by the
Institutional Review Board (IRB) at each participating institution
or via a reliance agreement with the central study IRB at Boston
Children’s Hospital. Each site abstracted data from the local med-
ical record and entered them into a central Red Cap database. The
data included demographics, disease characteristics at diagnosis,
treatment, and outcomes. When available, the original
anonymized written reports of specific studies including BM aspi-
rate and biopsy, cytogenetics, fluorescence in situ hybridization
(FISH), clonal analysis for paroxysmal nocturnal hemoglobinuria
(PNH), telomere flow-FISH analysis, immunological analyses, and
autopsies were uploaded for central review.
Submitted cases were included only if the diagnostic BM was
reported as hypocellular and the patient had at least two peripher-
al cytopenias: 1) absolute neutrophil count (ANC) < 0.5 x109/L; 2)
platelet count (Plts) < 20x109/L; 3) hemoglobin (Hb) < 8 g/dL.
Central review of diagnostic marrow slides was not feasible but
marrow pathology reports were reviewed to confirm that the mar-
row cellularity was  <25% or  hypocellularity was stated to be
consistent with the diagnosis of SAA without a specified percent-
age cellularity.  Patients with a local diagnosis of an inherited BM
failure syndrome were excluded from this study, as were subjects
with an HLA-matched sibling who went to transplant upfront.
Date of diagnosis was considered to be the date of the BM biopsy.
Date of treatment was considered the first day of IST, and all out-
comes were timed from the first day of treatment.  Structured
reporting of status and blood counts was required at initiation of
IST, as well as at 3, 6, 12, 24, 36, 48, and 60 months, and at last fol-
low up. 
Definitions
Overall survival (OS) was measured from the time from first
day of IST until death or date last known alive. Event-free survival
(EFS) was measured from the time from start of IST until an event
(death or start of a second therapy for SAA, either HSCT or a sec-
ond course of IST) or the date last known to be without an event. 
Response12 was defined using hemoglobin (Hb), absolute neu-
trophil count (ANC) and platelets (Plts). Complete response (CR),
very good partial response (VGPR)   and partial response (PR)
required the indicated levels in all three lineages as noted below;
no response (NR) was defined as failure in any lineage: 
CR: Hb ≥10 g/dL and ANC ≥1x109/L  and Plts ≥100x109/L
VGPR: Hb ≥8 g/dL and ANC ≥0.5x109/L and Plts ≥50x109/L
PR: Hb ≥8 g/dL and ANC ≥0.5x109/L and Plts ≥20x109/L
NR: Hb <8 g/dL or ANC <0.5x109/L or Plts <20x109/L
Patients receiving transfusions of packed red blood cells within
six weeks or platelets or granulocyte-colony stimulating factor (G-
CSF)/granulocyte/macrophage-colony stimulating factor (GM-
CSF) within two weeks of evaluation were deemed to have had
NR at that time point. An objective response (OR) was defined as
at least a PR (PR+VGPR+CR)  and a deep response (DR) was
defined as at least a VGPR (VGPR+CR). Duration of response
(DOR)  was defined as time from start of response to an event
(death or start of a second therapy for SAA, either HSCT or a sec-
ond course of IST). 
Statistical analysis
Summary statistics included median and range for continuous
variables and frequency and proportion for binary variables.
Fisher's exact test and Wilcoxon rank sum test were used to com-
pare proportions and medians, respectively. The proportion of
subjects with an OR, DR, and CR were reported along with the
exact binomial 95% confidence interval (95%CI).  OS, EFS and
DOR were estimated using the Kaplan-Meier method (log-log
transformation for Confidence Interval) and compared using the
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log-rank test. A Cox proportional hazards model was used to
compare EFS by treatment adjusting for co-variates of interest
[age, gender, time from initial IST treatment to 2nd treatment, and
lymphocytopenia (lymphocyte count <1x109/L)]. Reference
groups in this model were: IST treatment, age at second treatment
≥10 years, male gender, lymphocyte count at diagnosis ≥1x109/L.
An indicator variable was included in the model for missing lym-
phocyte data as these data were not provided for all subjects. The
median follow up among all subjects was 62 months. There was
80% power to detect differences of at least 16% difference in pro-
portions for 314 and 264 subjects, respectively (two-sided Fishers
exact test, alpha=0.05).  In terms of precision, the maximum
Confidence Interval width of the exact binomial 95%CI for an
observed proportion was 0.12 and 0.11, respectively, with n=314
and n=264. R language was used for analysis (R Core Team, 2016,
Vienna, Austria;  https://www.R-project.org). 
Results
Patients' characteristics at diagnosis
A total of 314 pediatric patients treated with IST for
SAA were identified by systematic retrospective chart
review across 25 NAPAAC institutions. Table 1 summa-
rizes baseline demographics of study subjects.  Nine
patients (0.03%) were 1-2 years of age.  Gender was even-
ly distributed. The population was racially diverse, reflect-
ing the ethnic diversity of North America.  A family histo-
ry of aplastic anemia, none of whom were first-degree rel-
atives, was noted in four patients.
Hepatitis was noted prior to diagnosis in 43 (13.7%)
patients, of whom 33 (12.5%) were treated with
hATG/cyclosporine (CyA). Laboratory features at diagno-
sis are summarized in Table 2.  PNH test results were
available at diagnosis for 140 patients and a PNH clone
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Table 1. Baseline demographics and characteristics.
                                                                                               Study subjects
                                                                                                All subjects                                                         hATG/CyA
Total subjects (N)                                                                                             314                                                                                     264
Male gender (N, %)                                                                                162 (51.6%)                                                                     141 (53.4%)
Median age in years at diagnosis (Range)                                          9.8 (1-20.3)                                                                      9.6 (1-20.3)
Race (N,%)                                                                                                                                                                                                    
White*                                                                                                      183 (58.3%)                                                                     157 (59.5%)
Black or African American                                                                    52 (16.6%)                                                                       42 (15.9%)
Asian                                                                                                           23 (7.3%)                                                                         19 (7.2%)
Other                                                                                                        33 (10.5%)                                                                        24 (9.1%)
Native Hawaiian or Other Pacific Islander                                        11 (3.5%)                                                                         11(4.2%)
Native American or Alaska Native                                                         1 (0.3%)                                                                           1 (0.4%)
Unknown                                                                                                    11 (3.5%)                                                                         10 (3.8%)
*Including Hispanic and Latino; hATG: horse anti-thymocyte globulin.; CyA: cyclosporin.
Table 2. Laboratory features at diagnosis.
                                                                                                   All subjects                                                  hATG/CyA subjects
                                                                           N                                                                                       N
                                                                     Evaluable                                      Value                           Evaluable                                        Value
PNH clone detected, N (%)                                        140                                                55 (39.3%)                                   109                                                   48(44%)
Median MCV, fL (IQR)                                                 273                                           89.1 (83.1-97.8 )                              234                                             89.1 (83.0-98.8)
MCV > 100fL, N, (%)                                                    273                                                55 (20.1%)                                   234                                                 51 (21.8%)
Median absolute reticulocyte                                    231                                                  19 (9,33)                                    190                                                 20 (10, 33)
count x109/L (IQR)                                                         
Median lymphocyte count/mL (IQR)                       260                                           1210 (600-1890)                              221                                            1260 (650-1950)
Lymphocyte count <1000/mL, N (%)                        260                                               110 (42.3%)                                  221                                                   89 (40.3)
PNH: paroxysmal nocturnal hemoglobinuria; MCV: mean red cell volume; fL: fentoliter; IQ: IQR: interquartile range.
Table 3. Treatment.
Treatment                                                              N (%) 
hATG+CyA                                                                 264 (84.1%)
hATG+Tacro                                                                15 (4.8%)
rATG+CyA or Tacro                                                   15 (4.8%)
CTX                                                                                19 (6.1%)
Unspecified ATG+CyA                                               1 (0.3%)
Tacro: tacrolimus,  CTX: cyclophosphamide; hATG: horse anti-thymocyte globulin; rATG: rabbit anti-thymocyte globulin; CyA: cyclosporine.
was noted in 55 (39.3%). In most cases, the clone size was
small [interquartile range (IQR): 0-0.12%]. Only 5 patients
had PNH clones larger than 10% (range: 12.56-28.4%) in
the granulocyte lineage and none had clinically evident
hemolysis or thrombosis at diagnosis. 
The most commonly investigated inherited BM failure
syndromes at diagnosis were Fanconi anemia,
Shwachman-Diamond syndrome, and dyskeratosis con-
genita. Fanconi anemia screening was negative for 292
patients (93%), 18 patients were not tested, and results
were not available for four subjects. Genetic testing for
Shwachman-Diamond syndrome was available for 46
patients (14.6%); all of these were negative.  Perhaps
reflecting the evolution of understanding the role of
dyskeratosis congenita in BM failure over the past five
years, telomere length was assessed at the time of diagno-
sis in only 115 patients (36.6%) and a report of a clinical
telomere flow-FISH test was available for 93 patients
(29.6%).  No patient exhibited a pattern suspicious for a
primary telomere disorder (telomeres <1st percentile in at
least 3 different lymphocyte subsets).13 However, telomere
lengths <1st percentile were found in total lymphocytes in
six patients, of whom only two had a complete 6-panel
analysis. 
The current diagnostic criteria for SAA includes an ARC
(absolute reticulocyte count) of <20-60x109/L.12,14,15
Many institutions relied on hemoglobin (Hb)  rather than
the ARC as a more clinically relevant indicator of ery-
throid hypoplasia to inform diagnosis and treatment deci-
sions.  Comparison of ARC versus Hb for the 231 subjects
with ARC <100 revealed a lack of concordance [(estimat-
ed Pearson correlation coefficient of 0.15 (95%CI: 0.02,
0.27)] between the commonly utilized diagnostic criteria
of ARC of <60 x109/L and significant anemia defined as
Hb <8 g/dL (Figure 1). A subset of patients meeting ARC
criteria of ARC <60 x109/L had Hb >8 g/dL (12.7%, 28 of
220), and conversely, some patients who did not meet
diagnostic criteria for ARC had Hb levels <8 g/dL (74%, 26
of 35). 
Treatment
Treatment groups are outlined in Table 3. The majority
of patients (n=264) received hATG plus CyA. Of these
subjects, one patient received hATG but switched to rab-
bit ATG (rATG) due to an anaphylactic reaction. Overall,
the demographics of the hATG/CyA population was sim-
ilar to that of the entire group (Tables 1-3). The small num-
ber of subjects in groups treated with alternative IST regi-
mens limited intergroup comparisons, and so only out-
comes of the entire population and that of the hATG/CyA
group were analyzed.     
Of the 282 subjects who were treated with hATG,187
(71%) received 40 mg/kg/day for four days, 77 were
dosed with a different regimen containing about the same
total dose of hATG, and in 18 the dose was not available.
CyA target  trough levels were variable (100-400), with
the majority 200-400. Following treatment with
hATG/CyA, data regarding the cyclosporine taper were
available for 194 patients. CyA was discontinued by six
months for 13 subjects, between 6-12 months for 40 sub-
jects, between 12-18 months for 34 subjects, between 18-
24 months for 37 subjects, and after two years for 34 sub-
jects.  CyA was not discontinued at last follow up for 36
subjects.
Median time from diagnosis to treatment for all subjects
was 24 days with an IQR of 12-40 days for the entire
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Figure 1. Correlation between absolute reticulocyte count and hemoglobin at
diagnosis. Absolute reticulocyte counts <100x109/L (n=231) were plotted
against the hemoglobin at diagnosis. CI: Confidence Interval.
Table 4. Best response to immunosuppressive therapy.
Response                        All treatments                    hATG/CyA
                                           N                     %                                          N                                %
CR                                    189                       60.2                       158               59.8
VGPR                                23                         7.3                         22                 8.3
PR                                      10                         3.2                          8                    3
NR                                     79                        25.2                        66                 25
NE                                     13                         4.1                         10                 3.8
Total                                 314                       100                       264               100
CR: complete response; VGPR: very good partial response; PR: partial response; NR:
no response; NE: not evaluable.
Table 5. Response outcome in each treatment group. 
Response Outcome                                     Treatment            Number of responses                    Response Rate (%)                                 95% CI*
Objective Response (CR+VGPR+PR)                    All                                       222                                                        70.7                                                      65.3, 75.7
                                                                                   hATG/CyA                                 188                                                        71.2                                                      65.3, 76.6
Deep Response (CR+VGPR)                                    All                                       212                                                        67.5                                                      62.0, 72.7
                                                                                   hATG/CyA                                 180                                                        68.2                                                      62.2, 73.8
Complete Response (CR)                                         All                                       189                                                        60.2                                                      54.5, 65.7
                                                                                   hATG/CyA                                 158                                                        59.8                                                      53.7, 65.8
*95% exact binomial Confidence Interval.
cohort. Similar time to treatment was noted for the
hATG/CyA group, with a median time from diagnosis of
23 days and an IQ range of 12-40 days. 
Response
For the cohort of 314 patients and for the subset treated
with hATG/CyA, median time to initial response was six
months (range: 3-48 months; IQR: 3-12 months).  Best
responses for all patients and for the hATG/CyA group are
summarized in Tables 4 and 5. 
For the 264 subjects treated with hATG/CyA, OR was
71.2% (95%CI: 65.3,76.6), consistent with results from
prior adult and pediatric studies.8,9,16-20 The quality of
response to hATG/CyA was good, with 59.8% (95%CI:
53.7,65.8) achieving a CR. Further, since the magnitude of
a partial platelet response carries clinical implications for
quality of life, the group attaining a deep response (Plts
≥50x109/L) was separately analyzed. A deep response was
achieved by 68.2% (95%CI: 62.2,73.8). No response (NR)
was noted in 66 subjects (25%) and 10 subjects (3.8%)
were not evaluable (NE, Tables 4 and 5). Responses at six
months post hATG/CyA were as follows: CR 21.6%,
VGPR 19.7%, PR 8%, NR 47%, NE 3.7%.
The duration of response among subjects who had any
initial response (CR, VGPR, or PR) is shown for all subjects
(Figure 2A) and for those treated with hATG/CyA (Figure
2B). The estimated probability of sustained response for
all subjects was 94% (95%CI: 89,96) at 24 months and
83% (95%CI: 76,88) at 60 months.  For the subset of sub-
jects treated with hATG/CyA, the estimated probability
of sustained response was 94% (95%CI: 90,97) at 24
months and 84% (95%CI: 76,90) at 60 months. However,
there was no plateau for loss of response observed over
time even after five years post treatment.
Factors potentially affecting OR or DR for subjects treat-
ed with hATG/CyA were evaluated. No correlation with
response was detected for telomere lengths <1st or <10th
percentiles by flow-FISH, presence of a PNH clone, or red
cell macrocytosis (mean corpuscular volume ≥100 fL) 
(P ≥0.17) (Online Supplementary Table S1). There was also
no correlation between OR and median lymphocyte count
(1.1 vs. 1.3;Wilcoxon rank sum test, P=0.51). There was no
significant difference in median time from diagnosis to
treatment between responders and non-responders 
(P≥0.29) (Online Supplementary Table S1).
Survival
The estimated overall survival is summarized in Figure
3. Median follow up amongst all 314 subjects was 62
months (59 months for those still alive) and 61 months
among the hATG/CyA group (59 months for those still
alive). At the time of this analysis, there were 29 (9.3%)
deaths amongst all subjects; 21 (8%) amongst hATG/CyA-
treated patients. Estimated OS (95%CI) for the entire
cohort at 12, 24 and 60 months was 96% (95%CI: 94,98),
95% (92,97), and 92% (88,95), respectively (Figure 3A).
Among the subjects who received hATG/CyA, estimated
OS (95% CI) at 12, 24 and 60 months was 97% (94,99),
96% ( 93,98), and 93% (89,96), respectively (Figure 3B).
Six individuals died after one treatment with hATG/CyA
without receiving additional therapy. 
Of the 314 subjects, 119 (38%) died or required an addi-
tional therapy. The estimated EFS (95%CI) for all subjects
at 12, 24, and 60 months was 76% (95%CI: 70,80), 71%
(95%CI: 66,76), and 62% (95%CI: 56,68), respectively
(Figure 3C). The estimated median EFS for all subjects was
133 months. For patients treated with hATG/CyA, 98 of
264 subjects (37%) had an event. Median estimated EFS
was 133 months (Figure 3D).  Estimated EFS (95%CI) at
12, 24, and 60 months was 76% (95%CI: 70,81), 72%
(95%CI: 66,77), and 64% (95%CI: 57,69), respectively,
with events continuing to accrue even after five years post
treatment. 
No differences were detected in OS (P=0.13), EFS
(P=0.26), or response (P>0.25) versus age at diagnosis for all
subjects. No differences were detected in OS (P=0.09), EFS
(P=0.22), or response (P>0.20) versus age at diagnosis for
subjects treated with hATG/CyA.
Cytogenetics and clonal progression
Of the 271 patients in the cohort who had BM
metaphase cytogenetics (n=254) and/or FISH (n=133)
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Figure 2. Duration of response. Kaplan-Meier analysis of duration of response for (A) all subjects or (B) subjects treated with horse anti-thymocyte globulin
(rATG)/cyclosporine (CyA)  who achieved at least a partial response.
A B
assessments performed at diagnosis, seven (3%) had
detectable clonal chromosomal abnormalities (Table 6).
Six of these patients had follow-up cytogenetic assess-
ments. Two patients had a del(13q) clone at diagnosis,
which remained detectable through the duration of follow
up (range: 33-49 months) but was not associated with
acquisition of additional chromosomal abnormalities.  In
contrast, other small clones present at diagnosis, including
del(7q) in one patient and del(16q) in one patient, were no
longer detectable at follow-up assessment. 
Of the 171 total patients who had follow-up BM
metaphase cytogenetics (n=160) and/or FISH (n=109)
assessment performed after IST initiation, 12 (7.0%)
patients had evidence of new clonal chromosomal abnor-
malities (Table 7). One additional subject had a clonal
abnormality [+der(14;21)(q10;q10)] at 143 months from
the time of initial diagnosis; however, the baseline status
was unknown.  The most common genetic alteration after
IST was loss of chromosome 7 [either -7 or del (7q)] occur-
ring in six patients (3.5%), all of whom had normal cyto-
genetics at baseline. Three patients had a del(13q) clone
detected during follow-up BM assessments of which one
was acquired after treatment. Among those patients with
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Table 6. Clonal cytogenetic abnormalities at diagnosis and at follow up.
                                                                                          Acquired chromosomal abnormalities at diagnosis                                                     
Abnormality                             Status at follow up evaluation          Best response to initial therapy                     Second therapy               Outcome
del(13)(q12q21)*                                 Decreased clone size                                Relapse at two years                                                IST                            Death, MVA
del(7q)                                                            Not detected                                           CR by 12 months                                                  None                                Alive
add(11)(q23)*                                                       N.A.                                                     NR by 3 months                                                   None                                Alive
del(16)(q22)*                                               Not Detected                                            NR by 6 months                                                   BMT                                 Alive
add(14)(q11.2)*                                                    N.A.                                                     CR by 3 months                                                   None                                Alive
del(13)(q12q14)*                                 Decreased clone size                                     CR by 6 months                                                   None                                Alive
+mar[2]*                                                                N.A.                                                    NR by 12 months                                                    IST                                  Alive
*hATG/CyA subjects                                                                                                                                                                                                                                         
                                                                                    Post-treatment acquisition of chromosomal abnormalities                                               
Abnormality                                     Time from diagnosis                               Best response                                         Second                      Outcome
                                                  to first detection (months)                        to initial therapy                                      therapy                            
del(13q)(q14q22)*                                                 4.6                                                      CR by 6 months                                                   None                                Alive
i(X)(p10)*                                                                5.5                                                        CR by 3 years                                                     None                                Alive
der(5)t(1;5)(q11;q11.2)*                                     66.5                                                    NR by 12 months                                                    IST                                  Alive
-7*                                                                              37.1                                                     VGPR by 2 years                                                  None                                Alive
+14,-18*                                                                    4.5                                                     CR by 12 months                                                  None                                Alive
-7                                                                                 20                                                         NR by 2 years                                                      BMT                           Death, PNA
-5,-7,del(7q),del(20p)*                                         4.3                                                      NR by 6 months                                                   BMT                                 Alive
8*                                                                                 71                                                      VGPR by 5 years                                                  None                                Alive
i(2q)*                                                                       67.7                                                   Relapse at 2 years                                                  IST                                  Alive
-7,del(7q)*                                                              30.3                                                    NR by 12 months                                                    IST                            Death, ALL
del(7q22)*                                                                67                                                    Relapse at 2 years                                                  IST                            Death, AML
-7*                                                                                8                                                        NR by 6 months                                                     IST                                  Alive
*hATG/CyA subjects                                                                                                                                                                                                                                         
                                                                                                                                                              
NR: no-response; N.A.: not available; VGPR: very good partial response; CR: complete response; IST: immunosuppressive therapy; BMT: bone marrow transplant; MVA: motor
vehicle accident;  PNA: pneumonia; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia.
Table 7. Comparison of baseline cytogenetic clones with subsequent clonal abnormalities.
Baseline*                                              Follow Up                                                                                            
                                  Normal                 Abnormal     Not Evaluable                        Total 
                                                  N                        %                            N                         %                           N                        %                             
Normal                                               137                           51.9                                12                             4.6                              115                          43.6                               264
Abnormal                                             3                             42.9                                 2                             28.6                               2                            28.6                                 7
Not Evaluable                                    16                            37.2                                 1                              2.3                               26                           60.5                                43
Total                                                   156                           49.7                                15                             4.8                              143                          45.5                               314
*Cytogenetics or fluorescence in situ hybridization at diagnosis.
Table 8. Subsequent treatments.
Subsequent                  All patients (N=314)           hATG/CyA (N=264)
Treatment                          N               %                 N                   %
2nd therapy                               110                35                   92                      35
3rd therapy                                 35                 11                   33                      13
4th therapy                                  3                   1                     3                        1
no clonal abnormalities at presentation, but who subse-
quently developed abnormalities at follow up, the median
time to observe an abnormality was 25.2 months (range:
4.3-71.0 months; IQ range: 5.3-66.6 months). Interestingly,
only four patients had BM pathology reports confirming
the diagnosis of myelodysplastic syndrome of whom two
proceeded to HSCT prior to further clonal evolution. One
patient developed acute lymphoblastic leukemia and three
developed acute myeloid leukemia.
Complications
Complications following initiation of IST were com-
mon with bleeding (gastrointestinal, intracranial, hema-
turia or other significant hemorrhage) being most frequent
and reported in 74 (23.6%) of all subjects (23.5% of
hATG/CyA subjects). Infections, including bacteremia,
fungal infections, cellulitis, meningitis, or pneumonia,
were reported in 177 (56.4%) of all subjects (53.4% of
hATG/CyA subjects). Renal failure requiring dialysis was
reported in five patients (1.6%), all in the hATG/CyA
group (1.9%). Causes of death classified by type of thera-
py and survival interval are detailed in Online
Supplementary Table S2.
Outcomes after second-line therapy
Subsequent treatments following upfront hATG/CyA
are summarized in Table 8.
Overall, 110 of 314 (35%) subjects received a second
treatment, 35 of the 110 a third treatment, and three a
fourth therapy.  
Of the 38 patients undergoing HSCT for second-line
therapy, response to initial treatment with hATG/CyA
was as follows: 31 had refractory disease and seven had
relapsed disease.  Of the seven patients undergoing HSCT
for relapsed disease, responses to initial hATG/CyA at
three months and six months were as follows: one  CR
and six NR at three months; three CR, one VGPR, two
NR, and one NE at six months.  Of the 52 patients receiv-
ing a second IST treatment, response to initial treatment
with hATG/CyA was as follows: 36 had refractory dis-
ease, 15 had relapsed disease, and one patient lacked avail-
able response data.  Of the 15 patients undergoing second
IST for relapsed disease, responses to initial hATG/CyA at
three months and six months were as follows:  one CR,
one  VGPR,  one  PR, and 12 NR at three  months; one  CR,
four  VGPR, five PR, and five NR at six  months. Two addi-
tional patients received tacrolimus for relapsed disease.
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Figure 3. Immunosuppressive therapy: survival. Kaplan-Meier analysis of overall survival for (A) all subjects or (B) subjects treated with horse anti-thymocyte globulin
(rATG) / cyclosporine (CyA). Kaplan-Meier analysis of event-free survival for (C) all subjects or (D) subjects treated with hATG/CyA.  
A B
C D
Additional information is provided in the Online
Supplementary Table S1.
For the 80 subjects who underwent second-line HSCT
therapy, donors included 12 matched sibling donors, 61
matched unrelated donors (MUD), and 7 haplo-identical
donors.  Stem cell sources within the MUD cohort consist-
ed of 42 from BM, five from peripheral blood, 12 from
cord blood, and two without available data. Transplant
preparative regimens varied widely both within and
between institutions.
Overall survival for patients receiving a second treat-
ment is shown in Figure 4A. Among all subjects (n=110)
and the hATG/CyA group (n=92) who received second-
line treatment, 20 (18.2%) and 15 (16.3%) died, respec-
tively. In a Cox proportional hazards model, there was no
significant effect of time from IST to second treatment on
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Figure 4. Outcomes after second-line therapy for relapsed/refractory disease.  Kaplan-Meier analysis of (A) overall survival and (B) event-free survival for all subjects
or subjects treated with horse anti-thymocyte globulin (rATG)/cyclosporine (CyA). (C) Log-rank test was used to compare event-free survival after second-line treat-
ment with hematopoietic stem cell transplantation (HSCT) versus immunosuppressive therapy (IST)  for all subjects or subjects treated with hATG/CyA. 
A
B
C
OS for either the entire cohort (HR=1.0, 95%CI: 0.98,1.02;
P=0.76) or the hATG/CyA group (HR=0.99, 95%CI:
0.98,1.03; P=0.69).  EFS is shown in Figure 4B.  Among all
subjects receiving second-line treatment (n=110), 49
(44.6%) failed with a median time to failure of 88.5
months (95%CI: 45.6,131.5). Among the 92 subjects from
the hATG/CyA group receiving second-line treatment, 43
(46.7%) failed with a median time to failure of 64.4
months (95%CI: 44.2,131.5) 
Outcomes of second-line treatment with HSCT versus
IST were compared for all subjects and for the hATG/CyA
treatment group.  Among all subjects receiving subsequent
treatment (n=110), 45 received HSCT and 65 received IST.
Among the hATG/CyA group receiving second-line treat-
ment (n=92), 38 received HSCT and 54 received a second
course of IST.  Due to the significantly longer follow up
with second-line IST as compared to bone marrow trans-
plantation  for both the entire cohort (69 vs. 36 months;
log rank, P=0.05) and the hATG/CyA group (74 vs. 36
months; log rank, P=0.026), the data were censored at 36
months in the analysis to minimize the impact of differen-
tial follow up. The analysis shows that EFS is significantly
longer with the second-line treatment of HSCT compared
with IST (log rank, P≤0.011) (Figure 4C); this effect
remains after adjusting for other variables (Online
Supplementary Figure S1).
Discussion
We report a multi-institutional study of the presentation
and outcomes of 314 North American pediatric SAA
patients treated with IST. Although retrospective studies
are limited by potential confounding factors and data
availability, this multicenter study provides a contempo-
rary analysis of the diagnostic evaluation and treatment
outcomes for pediatric SAA. Since the natural history,
risks, benefits, and outcomes of treatments are not identi-
cal between children versus adults with SAA, the study of
rare diseases such as pediatric SAA requires collaborative
effort through large consortia with the goal of improving
diagnosis and treatment. As with any rare disease, nation-
al registries would greatly advance the prospective study
of pediatric aplastic anemia.
Although traditionally reticulocytopenia has been used
as a diagnostic criterion for SAA, in this large study, retic-
ulocytopenia with an ARC <60x109/L did not correlate
with a Hb <8 g/dL in a subset of patients. We found that
the majority of clinicians were using clinically significant
anemia and need for transfusion, rather than the ARC, to
inform diagnosis and initiation of therapy.  Indeed, in the
setting of severe anemia without BM failure, the reticulo-
cyte count would be expected to be markedly higher, so
even an ARC within the normal range may be a sign of
impaired erythropoiesis.
Red cell macrocytosis may be indicative of the time
frame from evolution of reduced hematopoietic stem cell
numbers and clinically significant cytopenias. In addition,
red cell macrocytosis may be associated with dysplastic
processes. However, no association between macrocytosis
and likelihood of hematologic response or survival was
observed. Lymphopenia in pediatric patients with other
cytopenias may be seen with primary immunological dis-
orders; however, no association with response was
observed. Development of cytogenetically abnormal
clones or overt hematologic clonal disease was rare,
although post-treatment marrow surveillance was not uni-
formly conducted or captured due to the retrospective
nature of this analysis. 
A correlation between short leukocyte telomere length
at diagnosis, measured by quantitative polymerase chain
reaction, with increased risk of relapse, clonal evolution,
and reduced survival has been reported.21 Since current
clinically available telomere length testing utilizes flow-
FISH,13 we explored whether the results of this clinical
telomere length assay correlated with outcomes.  We did
not detect a correlation between telomere lengths less than
either the 1st or 10th percentile for age with response to IST.
We observed some notable differences from reported
outcomes for adult SAA patients treated with hATG/CyA.
Since the magnitude of blood count recovery is especially
important to support normal growth and activity in chil-
dren, we examined the quality of response to IST. Of
those pediatric patients who responded to hATG/CyA,
the quality of response was high, with 59.8% achieving a
CR and 68.2% achieving a DR. In contrast, typical rates of
CR cited for adults is 10%.12  In addition, a lower rate of
clonal progression was noted for children in comparison
to the 10-15% clonal progression reported in adults,
although this observation is potentially limited by the ret-
rospective nature of this study and short follow-up
time.22,23 However, EFS was low, with events continuing to
accrue well past five years post IST without an apparent
plateau. EFS is of particular concern for pediatric patients
given their long future lifespan. Accordingly, both clinical
decisions and evaluation of new therapies should be based
on pediatric data whenever possible, rather than on
extrapolation of data from adult cohorts.  For patients
with refractory or relapsed disease, EFS was superior for
patients receiving second-line treatment with HSCT com-
pared with IST even after adjusting for age, gender, time
from initial IST to second treatment, and lymphocytope-
nia. A prospective study of 21 pediatric SAA patients
receiving a second course of IST for refractory disease
reported anaphylaxis in three patients and a trilineage
response in only two (11%) of the remaining 18 patients,
with a 5-year failure-free survival of only 9% at five years
post second-line therapy.6 Together with the excellent
contemporary outcomes of MUD transplantation,24-26
these data strongly suggest that allogeneic transplantation
with a MUD is a superior second-line therapy for relapsed
or refractory SAA after IST for pediatric patients. In addi-
tion, these data suggest a potential role for MUD HSCT as
upfront therapy in young patients. A randomized pilot
and feasibility trial comparing hATG/CyA versus MUD
HSCT in newly diagnosed SAA patients lacking an HLA-
matched family donor is currently underway.
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